Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > 06667 MEGA GENOMICS > Detailed Quotes

06667 MEGA GENOMICS

Watchlist
10.880
-0.120-1.09%
Trading Session  02/01 14:03 CCT
High
11.000
Open
11.000
Turnover
1.04M
Low
10.400
Pre Close
11.000
Volume
96.80K
Market Cap
2.60B
P/E(TTM)
36.15
52wk High
21.000
Shares
239.23M
P/E(Static)
26.93
52wk Low
10.100
Float Cap
2.60B
Bid/Ask %
93.94%
Historical High
21.000
Shs Float
239.23M
Volume Ratio
1.01
Historical Low
10.100
Dividend TTM
--
Div Yield TTM
--
P/B
3.43
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.04%
Amplitude
5.46%
Avg Price
10.706
Lot Size
200
Float Cap
2.60B
Bid/Ask %
93.94%
Historical High
21.000
Shs Float
239.23M
Volume Ratio
1.01
Historical Low
10.100
Dividend TTM
--
P/B
3.43
Dividend LFY
--
Turnover Ratio
0.04%
Amplitude
5.46%
Avg Price
10.706
Lot Size
200
Price Forecast

News

Comment

No More
Company Overview More
Maingene Co., Ltd. (“Maingene” or the “Company”, stock code: 6667.HK) is a leading genetic testing platform company in China, focusing on consumer-grade genetic testing and cancer screening services. Since its establishment in 2016, the company has performed more than 12 million genetic tests, with an average of more than 246,000 tests per month in 2021. According to Frost & Sullivan's data, the company is the largest consumer genetic testing platform in China based on the cumulative number of tests carried out; based on the number of tests carried out in 2020, the company is also the largest cancer screening genetic testing platform in China. The company has launched dozens of testing services, covering a wide range of fields such as nutrition and metabolism, cancer risk assessment, chronic disease susceptibility, cancer screening and infectious disease diagnosis, to meet the growing demand of consumers for preventive medicine. With an advanced integrated technology platform system and a market-leading level of process automation, the company's high-throughput testing platform can process 50,000 samples per day, which is the largest capacity in the industry. At the same time, the company is actively exploring potential applications of genetic technology in health management, precision medicine, and new drug development. As of December 31, 2021, the company has partnered with more than 1,400 healthcare institutions in more than 340 cities in China. In addition, the company has established strategic cooperation with many e-commerce and online healthcare platforms to extend services to more regions, so that more people can pass genetic tests and better manage their health. Maingene is committed to unlocking genetic mysteries and protecting human health with advanced genetic testing technology and inclusive genetic testing services.
CEO: Lin Lin
Market: Hong Kong motherboard
Listing Date: 06/22/2022
Paper Trade More
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist